New Information | Series C financing of over 100 million yuan marks the first round of financing for Shengshi Taike, paving the way for commercialization of core innovative products

Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, has been selected as a "Double Innovation Talent" in Jiangsu Province

Recently, the "Double Innovation Talent Plan" organized by the Jiangsu Provincial People's Government and the Provincial Talent Office was awarded a certificate of selection, and Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, was selected for the "2023 Jiangsu Province High level Innovation and Entrepreneurship Talent Introduction Plan". The Shengshi Taike R&D team led by Dr. Wang Tong is committed to the development of high-quality and differentiated small molecule innovative drugs, aiming to address major clinical pain points in the fields of blood sugar reduction, anti-tumor, and autoimmune diseases.

Brainstorming | Exploring the Ocean of Stars through Metabolism

With the advancement of the Healthy China 2030 Plan, chronic disease drugs have become a focus of pharmaceutical research and development. Among them, the development of cardiovascular, lipid-lowering, and hypoglycemic and weight loss drugs has become a hot track in the industry. Recently, R&D clients and Haomai Technology held a "brainstorming session" in Zhuhai, focusing on clinical needs, industry trends, and the latest drug development trends in the field of metabolic diseases. Dr. Yu Qiang, founder and CEO of Shengshi Taike, attended the conference and explored the vast universe of chronic disease drugs with guests starting from metabolism.

Shengshi Taike has once again been listed on the "Top 50 Most Influential Medical and Health Enterprises in China" list

Recently, CHC Medical Consulting and CITIC Securities officially released the "2023 China Healthcare Industry Investment and Financing Honor List". As an innovative pharmaceutical company in the commercialization stage, Shengshi Taike has once again been listed in this category and won the honor of being one of the top 50 most influential medical and health enterprises in China in 2023.

Dr. Yu Qiang: Facing Industry Changes and Embracing the Future of AI

Recently, the 9th BIOCHINA (EBC) E-commerce Biotech Industry Conference was held at the Suzhou International Expo Center. Dr. Yu Qiang, founder and CEO of Shengshi Taike and Secretary General of Xinyao Club, participated in this conference and planned the "Small Molecule Innovative Drug Research and Development Forum". More than ten outstanding representatives from the industry were specially invited to discuss new technologies and targets of small molecule drugs, and explore with on-site guests how small molecules can play an important role in future drug research and development to better meet clinical needs.